Breast Cancer Research and Treatment

, Volume 83, Issue 1, pp 25–32 | Cite as

Cost of Illness Associated with Metastatic Breast Cancer

  • S. Rao
  • J. Kubisiak
  • D. Gilden
Article

Abstract

This study assesses cost of illness of metastatic breast cancer (MBC) patients over a specific period of time as observed in Medicare program expenditure data. Incident cases of MBC from 1997 to 1999 were included. Direct care cost data were obtained from Medicare claims from a 5% national sample of program beneficiaries. Costs to the health care system were determined from the date of first diagnosis of MBC to the end of follow-up. A matched case-control study provided comparison of Medicare payments in cancer and non-cancer patients. A total of 397 MBC patients were identified and followed for an average of 16.2 months. The mean total cost was US$ 35,164 per MBC patient and US$ 4176 per person for the control group. Over the follow-up period, the MBC patients averaged 1.7 inpatient admissions per patient and 14.4 inpatient days per admission. The control group averaged 0.3 inpatient admissions per patient and 1.6 inpatient days per admission. Home health aide for MBC averaged one visit every 2 weeks. The direct costs for the older MBC patients were less than the direct costs of the younger MBC group. Multivariate regression analysis showed that as the age increased, the Medicare costs decreased within the MBC cohorts. Less combination treatments were provided for older MBC patients. Cost of illness was inversely proportional to age.

cost offsets cost of illness direct care costs Medicare costs metastatic breast cancer treatment distributions 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brown ML, Lipscomb J, Snyder C: The burden of illness of cancer: economic costs and quality of life. Annu Rev Public Health 22: 91–113, 2001Google Scholar
  2. 2.
    Ries LAG, Eisner MP, Kosary CL: SEER Cancer Statistics Review, 1973-1997. National Cancer Institute, Bethesda MD, 2000Google Scholar
  3. 3.
    Surveillance, Epidemiology, and End Results (SEER) Registry Program for Public-use: Division of Cancer Control and Population Sciences, Cancer Surveillance Research Program, National Cancer Institute, Cancer Statistics Branch, 2000Google Scholar
  4. 4.
    American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 2000Google Scholar
  5. 5.
    Baker MS, Kessler LG, Urban N, Smucker RC: Estimating the treatment costs of breast and lung cancer. Med Care 29: 40–49, 1991Google Scholar
  6. 6.
    Weitzner MA, McMillan SC: The caregiver quality of life index-cancer (CQOLC) scale. Revalidation in a home hospice setting. J Palliat Care 15(2): 13–20, 1999Google Scholar
  7. 7.
    Wai ES, Trevisan CH, Taylor SCM, Mates D, Jackson JS, Olivotto IA: Health system costs of metastatic breast cancer. Breast Cancer Res Treatment 65: 233–240, 2001Google Scholar
  8. 8.
    Fireman BH, Quesenberry CP, Somkin CP, Jacobson AS, Baer D, West D, Potosky AL, Brown ML: Health care financing review 18(4): 51–76, 1997Google Scholar
  9. 9.
    Zbrozek AS, Gilden DM, Kubisiak J, Lee A: Burden of illness study of lung, pancreatic and renal cell cancer. Annual Meeting of the American Society of Clinical Oncology, May 2002 (Abstract 2592)Google Scholar
  10. 10.
    Hayman JA, Langa KM, Kabeto MU, Katz SJ, DeMonner SM, Chernew ME, Slavin MB, Fendrick AM: Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol 19(13): 3219–3225, 2001Google Scholar
  11. 11.
    Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P: Stage, age, comorbidity and direct costs of colon, prostate and breast cancer care. J Natl Cancer Inst 87(6): 417–426, 1997Google Scholar
  12. 12.
    Greenfield S, Blanco DM, Elashoff RM, Ganz PA: Patterns of care related to age of breast cancer patients. JAMA 257(20): 2766–2770, 1987Google Scholar
  13. 13.
    Hunt KE, Fry DE, Bland KI: Breast carcinoma in the elderly patient: an assessment of operative risk, morbidity and mortality. Am J Surg 140: 339–342, 1980Google Scholar
  14. 14.
    Begg CB, Cohen JL, Ellerton L: Are the elderly predisposed to toxicity from cancer chemotherapy: an investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 3: 369–374, 1980Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • S. Rao
    • 1
  • J. Kubisiak
    • 2
  • D. Gilden
    • 2
  1. 1.Global Health Outcomes Assessment, Wyeth ResearchCollegeville
  2. 2.Health OutcomesJEN AssociatesCambridgeUSA

Personalised recommendations